Back to News
Market Impact: 0.35
Axsome Therapeutics Q3 Sales Rise Across Key Brands; Pipeline Milestones Set For 2027
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Axsome Therapeutics reported third-quarter 2026 net product revenue of $259.7 million, up 52% from $171.0 million a year earlier. The company attributed growth to AUVELITY, SUNOSI and SYMBRAVO; the article also mentions neuroscience progress but is cut off before providing details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
AXSM0.70
More News
- Marvell to buy Lumentum in $115 billion deal in AI data-center bet
- Palantir reports booming U.S. commercial revenue growth, topping government for first time
- Anthropic releases amended IPO prospectus with third-quarter financials
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- The AI boom is facing another supply crunch. This time it’s the amount of capital available to feed Silicon Valley’s endless need for cash
- Anthropic to Spend $895 Billion in the Years Ahead